Direct Healthcare Professional Communication

March 2022

Mavenclad (Cladribine) – risk of serious liver injury and new recommendations about liver function monitoring

Dear Healthcare professional,

The Egyptian Pharmaceutical Vigilance Center of the Central Administration for Pharmaceutical Care at The Egyptian Drug Authority would like to inform you of the following:

Summary

• Liver injury, including serious cases, has been reported in patients treated with Mavenclad.

• Before initiating treatment, a detailed patient history of underlying liver disorders or episodes of liver injury with other medicines should be undertaken.

• Liver function tests including serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be assessed prior to initiation of therapy in year 1 and year 2.

• During treatment, liver function tests should be conducted, and repeated as necessary. In case a patient develops liver injury, treatment with Mavenclad should be interrupted or discontinued, as appropriate.

Background information on the security concerns

Mavenclad (cladribine) is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (MS).

Liver injury, including serious cases and cases leading to discontinuation of treatment, has been reported in patients treated with Mavenclad. A recent review of available safety data has concluded on an increased risk for liver injury following treatment with Mavenclad.

Most cases of liver injury concerned patients with mild clinical symptoms. However, in rare cases, a transient transaminase elevation exceeding 1000 units per litre and jaundice was described. Time to onset varied, with most cases occurring within 8 weeks after the first treatment course.

The review of liver injury cases did not identify a clear mechanism. Some patients had a history of previous episodes of liver injury with other medicines or had underlying liver disorders. Data from clinical trials did not suggest a dose dependent effect.

Liver injury has been included in the product information of Mavenclad as an adverse drug reaction of uncommon frequency. In addition, the product information has been updated with new warnings and precautions regarding liver injury, including recommendations to obtain patient history for underlying

21st Abdel-Aziz Al-Saud, Manial Al-Roda,Cairo
pv.head@edaegypt.gov.eg; pv.safety@edaegypt.gov.eg;
Tel.: 237484988 Ext.:1470

liver disorders or previous liver injury, and to assess liver function tests prior to treatment initiation in year 1 and 2. The prescribers' guide and the patient guide of Mavenclad will be updated to include information about liver adverse events.

Patients should be advised to report immediately to their healthcare professional any signs or symptoms of liver injury.

References

https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-mavenclad-cladribine-risk-serious-liver-injury-new_en.pdf

Call for reporting

The Egyptian Pharmaceutical Vigilance Center is reminding HCP and public to report any safety information regarding human medicinal products including adverse drug reactions, medications errors, lack of efficacy and other medicine related problems through the following contacts:

The Egyptian Pharmaceutical Vigilance Center

Address: 21 Abd El Aziz Al Soud Street, El-Manial, Cairo, Egypt, And PO Box: 11451
Telephone: (+2)02 25354100, Extension: 1470 Fax: +202 – 23610497

Hotline: 15301

Email: Pv.follow-up@edaegypt.gov.eg

Online reporting: https://primaryreporting.who-umc.org/EG
QR Code:

Company contact point

Merck Ltd. Egypt l Building 4 Section 1150, End of Abdel Hamid Badawi St. l Sheraton Buildings District, 11361 l Cairo - Egypt

Tel: +202.22686614 /15 / 21 l Fax: +202.22686617

e-mail: Drug.safety.egypt@merckgroup.com

website: www.merckgroup.com

21st Abdel-Aziz Al-Saud, Manial Al-Roda,Cairo
pv.head@edaegypt.gov.eg; pv.safety@edaegypt.gov.eg;
Tel.: 237484988 Ext.:1470